signalp 4.1 Search Results


96
Santa Cruz Biotechnology myc
Myc, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/c-Myc+Antibody/pm38432633-166-22-29
Average 96 stars, based on 1 article reviews
myc - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology anti pld1
Translocated PKCγ becomes associated with PLCα2 and activates <t>PLD1.</t> (A) Perinuclear colocalization of PKCα with PLCγ2; and PKC with PLD1 15 min after lacritin addition. Bars, 25 μm (left) and 10 μm (right). (B) Anti-PLCγ2 immunoprecipitate of homogenate from cells treated for 15 min with lacritin contains PKCα and PLD1. (C) Lacritin dose– response analysis of PLCγ2 phosphorylation in anti-PLCγ2 immunoprecipitates of homogenate from 15-min–treated cells. (D) Lacritin addition promotes activation of PLD in a biphasic dose-dependent manner. Activation is abrogated by knockdown of PKCα using siRNA D7, which has little or no effect on FBS-stimulated PLD activation. Data are presented as the mean ± the SEM.
Anti Pld1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/PC-PLD1+Antibody/pmc01761701-286-17-7
Average 94 stars, based on 1 article reviews
anti pld1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

97
Cell Signaling Technology Inc p jnk thr183 tyr185 cell signaling 9251 rabbit polyclonal
Translocated PKCγ becomes associated with PLCα2 and activates <t>PLD1.</t> (A) Perinuclear colocalization of PKCα with PLCγ2; and PKC with PLD1 15 min after lacritin addition. Bars, 25 μm (left) and 10 μm (right). (B) Anti-PLCγ2 immunoprecipitate of homogenate from cells treated for 15 min with lacritin contains PKCα and PLD1. (C) Lacritin dose– response analysis of PLCγ2 phosphorylation in anti-PLCγ2 immunoprecipitates of homogenate from 15-min–treated cells. (D) Lacritin addition promotes activation of PLD in a biphasic dose-dependent manner. Activation is abrogated by knockdown of PKCα using siRNA D7, which has little or no effect on FBS-stimulated PLD activation. Data are presented as the mean ± the SEM.
P Jnk Thr183 Tyr185 Cell Signaling 9251 Rabbit Polyclonal, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/Phospho-SAPK%2FJNK+(Thr183%2FTyr185)+Antibody/pm24704720-463-71-74
Average 97 stars, based on 1 article reviews
p jnk thr183 tyr185 cell signaling 9251 rabbit polyclonal - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc phospho β catenin
Expression of AnkB, <t>Total</t> <t>β-Catenin</t> and Phosphorylated β-Catenin After Tideglusib Administration in Ank2 -cKO Mice (A) Validation of the Ank2 -cKO murine model via immunoblotting, and (B) quantitative analysis of AnkB protein levels in hearts of both Ank2 fl/fl and Ank2 -cKO mice. (C-D) Immunoblots and quantitative analysis of total β-catenin and GAPDH in Ank2 -cKO-TD- vs vehicle-treated mice. (E-F) Immunoblots and quantitative analysis of phosphorylated β-catenin and GAPDH in Ank2 -cKO TD- vs vehicle-treated mice. Data presented using mean ± SEM and compared using analysis of variance with Tukey post hoc test or Student's t -test, n = 3-4, ∗∗ P < 0.01. Abbreviations as in and .
Phospho β Catenin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/Phospho-beta-Catenin+(Ser33%2F37%2FThr41)+Antibody/pmc12399120-40-23-32
Average 96 stars, based on 1 article reviews
phospho β catenin - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc non phospho active β catenin
Effect of ROBO1 or ROBO2 functional impairment in branching morphogenesis. a The upper panel is representative of untreated lung explants (0 ng/mL) at D0; the bottom panel represents lung explants treated with recombinant IgG protein (0 ng/mL) and several doses of recombinant ROBO1 or ROBO2 proteins at day 4 (D4). b Morphometric analysis of the number of peripheral airway buds of fetal rat lung explants treated with increasing concentrations of recombinant ROBO1 (black) and ROBO2 (gray) proteins. Results are expressed as the D4/D0 ratio. c Examples of representative blots are showed for each analysed protein. Protein expression levels of d ROBO; e SOX2; f SOX9; g <t>total</t> <t>β-Catenin;</t> h non-phospho (active) β-Catenin; and i BMP4 in normal explant cultures treated with recombinant rat ROBO1 Fc Chimera for ROBO1 inhibition (black line) or recombinant human ROBO2 Fc Chimera for ROBO2 functional impairment (gray line). Recombinant human IgG Fc was used as control (IgG). n ≥ 9 per protein/condition. Each lane represents a pooled-tissue sample, and relative expression was determined against β-Tubulin and IgG. The data are presented as means ± SEM. p < 0.05: α vs. IgG
Non Phospho Active β Catenin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/Non-phospho+(Active)+beta-Catenin+(Ser33%2F37%2FThr41)+Antibody/pmc07672875-58-62-70
Average 95 stars, based on 1 article reviews
non phospho active β catenin - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit anti non phospho active β catenin ser33 37 thr41
Effect of ROBO1 or ROBO2 functional impairment in branching morphogenesis. a The upper panel is representative of untreated lung explants (0 ng/mL) at D0; the bottom panel represents lung explants treated with recombinant IgG protein (0 ng/mL) and several doses of recombinant ROBO1 or ROBO2 proteins at day 4 (D4). b Morphometric analysis of the number of peripheral airway buds of fetal rat lung explants treated with increasing concentrations of recombinant ROBO1 (black) and ROBO2 (gray) proteins. Results are expressed as the D4/D0 ratio. c Examples of representative blots are showed for each analysed protein. Protein expression levels of d ROBO; e SOX2; f SOX9; g <t>total</t> <t>β-Catenin;</t> h non-phospho (active) β-Catenin; and i BMP4 in normal explant cultures treated with recombinant rat ROBO1 Fc Chimera for ROBO1 inhibition (black line) or recombinant human ROBO2 Fc Chimera for ROBO2 functional impairment (gray line). Recombinant human IgG Fc was used as control (IgG). n ≥ 9 per protein/condition. Each lane represents a pooled-tissue sample, and relative expression was determined against β-Tubulin and IgG. The data are presented as means ± SEM. p < 0.05: α vs. IgG
Rabbit Anti Non Phospho Active β Catenin Ser33 37 Thr41, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/Non-phospho+(Active)+beta-Catenin+(Ser33%2F37%2FThr41)+Rabbit+mAb/pmc06711805-141-15-11
Average 96 stars, based on 1 article reviews
rabbit anti non phospho active β catenin ser33 37 thr41 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc phosphorylated β catenin
<t>β-catenin</t> is essential for CUG2-induced CSC-like phenotypes. (A) A549-VEC and A549-CUG2 cells were separated into cytosolic and nuclear <t>fractions.</t> <t>β-catenin</t> expression was determined by performing western blot analysis with an anti-β-catenin antibody. Phosphorylation states of β-catenin following treatment were detected using antibodies against <t>Ser33/Ser37/Thr41,</t> <t>Ser45</t> and <t>Ser675</t> of β-catenin. The cytosolic and nuclear fractions were confirmed by detecting actin and Sp1, respectively. (B) Total RNAs (3 µ g) were isolated from the A549-VECand A549-CUG2 cells, and cDNAs were synthesized using reverse transcriptase II. β-catenin gene sequences were amplified using specific primers by using an optimized PCR cycle and were visualized on 1.5% agarose gels following ethidium bromide staining. β-actin was used as an internal control. (C) A549-VEC and A549-CUG2 cells were transfected with the Top-Flash (1 µ g) or Fop-Flash (1 µ g) luciferase reporter vector and were harvested at 48 h after the transfection. Transfection efficiency was normalized with that of the β-galactosidase reporter vector pGK-βgal (1 µ g) during the measurement of luciferase activity. Results are an average of three experiments; bars indicate the means ± SD ( *** P<0.001, A549-VEC vs A549-CUG2 cells). (D) Transfection of efficiency of β-catenin siRNAs (#1 or #2) was confirmed by western blot analysis. (E) Migration of A549-CUG2 cells was measured with the wound healing assay at 24 h after control or β-catenin siRNAs (#1 and #2) transfection. Wound closure areas were monitored using a phase-contrast microscope at ×100 magnification, and the assay was repeated twice. (F) Invasion of A549-CUG2 cells transfected with control or β-catenin siRNAs (#1 and #2) was determined using the 48-well Boyden chamber. The chamber was assembled using Matrigel-coated polycarbonate filters. Scale bar indicates 100 µ m, and the assay was repeated twice. Each assay was performed in triplicate, and error bars indicate the means ± SD ( *** P<0.001, control vs. β-catenin siRNA). (G) A549-CUG2 cells (1,000 cells per well) transfected with control or β-catenin siRNAs (#1 and #2) were seeded in ultra-low attachment plates for 2, 4, or 6 days. The assay was performed in triplicate, and error bars indicate the means ± SD ( ** P<0.01 and *** P<0.001, control vs. β-catenin siRNA). Scale bars indicate 50 µ m. CUG2, cancer-upregulated gene 2.
Phosphorylated β Catenin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/Phospho-beta-Catenin+(Ser45)+Antibody/pmc06411349-40-10-24
Average 94 stars, based on 1 article reviews
phosphorylated β catenin - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc dqgscgscwafgaveaisdr at5
Peptides identified by LC ESMS from HNE-modified cathepsin B
Dqgscgscwafgaveaisdr At5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/CD45+Rat+mAb/pmc02373537-97-95-135
Average 90 stars, based on 1 article reviews
dqgscgscwafgaveaisdr at5 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Proteintech fbxo41
Peptides identified by LC ESMS from HNE-modified cathepsin B
Fbxo41, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/FBXO41+Antibody/bio_rxiv__2021__04__01__438131-153-80-81
Average 90 stars, based on 1 article reviews
fbxo41 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

96
MedChemExpress tgf β signaling pathway
Fig. <t>5</t> <t>AP3S1</t> exhibition in ovarian cancer single-cell sequencing results. A Single-cell sequencing results classifying cell subgroups in ovarian cancer tissues. B Cell subgroups identified as immune cell clusters. C Expression level of AP3S1 in immune cell clusters. D Proportions of various immune cells. E Proportions of different immune cells in various ovarian cancer samples. F Expression of AP3S1 in different immune cells. G Expression of DNA repair pathways in cell subgroups. H Expression of oxidative phosphorylation pathways in cell subgroups. I Expression <t>of</t> <t>TGF-β</t> pathways in cell subgroups
Tgf β Signaling Pathway, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/SRI-011381/pm38609993-123-25-32
Average 96 stars, based on 1 article reviews
tgf β signaling pathway - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

90
  Buy from Supplier

94
Cell Signaling Technology Inc triglyceride
(A) Expression of indicated mRNAs in Mefs was monitored by RT-qPCR after treatment of the cells with LiCl (10 mM) for 24 h. Results are expressed in arbitrary units (a.u.). (B) Expression of Dlk-1 mRNA in WT and KO Mefs was monitored by RT-qPCR at D0 and D7 of differentiation. Normalisation and expression was done as in <xref ref-type=Fig. 1D . (C) Western Blot detection of WT and KO Mef whole cell extracts treated as in (A) using an anti-Dlk-1 antibody is shown. (D) Prmt5 recruitment to A and B regions of the Dlk-1 promoter in WT and KO Mefs was analysed by ChIP at D0 and D7. Values are expressed as the percentage of immunoprecipitated (ip) chromatin relative to input and are the mean±s.e.m. of triplicates. No antibody (noAb) was used as negative control. (E) Immunoprecipitation was performed as in (D) to assess the recruitment of activated β-catenin (β-cat) to three regions of the Dlk-1 promoter: two of them encompass the TCF binding sites 1 and 2 (TCFbs1 and TCFbs2), the third one is B, as in (D). (F) Expression of Dlk-1 mRNA in sh Copr5 F442A-treated cells was monitored by RT-qPCR upon inactivation of Dlk-1 using sh RNA (sh Dlk-1 ) encoding retroviral particles. A scramble sh RNA (sh Scr ) was used as control. Normalisation and expression were performed as in (B). (G) O Red Oil staining at D6 of sh Copr5 F442A-treated cells infected as in (F). *: non specific band. " width="250" height="auto" />
Triglyceride, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/signalp+4%2E1/SPT16+Rabbit+mAb/pmc10227223__JAH3___12___e029470___s002-70-83-140
Average 94 stars, based on 1 article reviews
triglyceride - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Translocated PKCγ becomes associated with PLCα2 and activates PLD1. (A) Perinuclear colocalization of PKCα with PLCγ2; and PKC with PLD1 15 min after lacritin addition. Bars, 25 μm (left) and 10 μm (right). (B) Anti-PLCγ2 immunoprecipitate of homogenate from cells treated for 15 min with lacritin contains PKCα and PLD1. (C) Lacritin dose– response analysis of PLCγ2 phosphorylation in anti-PLCγ2 immunoprecipitates of homogenate from 15-min–treated cells. (D) Lacritin addition promotes activation of PLD in a biphasic dose-dependent manner. Activation is abrogated by knockdown of PKCα using siRNA D7, which has little or no effect on FBS-stimulated PLD activation. Data are presented as the mean ± the SEM.

Journal: The Journal of Cell Biology

Article Title: Restricted epithelial proliferation by lacritin via PKCα-dependent NFAT and mTOR pathways

doi: 10.1083/jcb.200605140

Figure Lengend Snippet: Translocated PKCγ becomes associated with PLCα2 and activates PLD1. (A) Perinuclear colocalization of PKCα with PLCγ2; and PKC with PLD1 15 min after lacritin addition. Bars, 25 μm (left) and 10 μm (right). (B) Anti-PLCγ2 immunoprecipitate of homogenate from cells treated for 15 min with lacritin contains PKCα and PLD1. (C) Lacritin dose– response analysis of PLCγ2 phosphorylation in anti-PLCγ2 immunoprecipitates of homogenate from 15-min–treated cells. (D) Lacritin addition promotes activation of PLD in a biphasic dose-dependent manner. Activation is abrogated by knockdown of PKCα using siRNA D7, which has little or no effect on FBS-stimulated PLD activation. Data are presented as the mean ± the SEM.

Article Snippet: In colocalization studies, we used anti-PKCα (H-7; Santa Cruz Biotechnology, Inc.), anti-PLCγ2 (Cell Signaling Technology), and purified anti-PLD1 (from serum 41) provided by D. Shields (Albert Einstein College of Medicine of Yeshiva University, New York, NY).

Techniques: Activation Assay

Expression of AnkB, Total β-Catenin and Phosphorylated β-Catenin After Tideglusib Administration in Ank2 -cKO Mice (A) Validation of the Ank2 -cKO murine model via immunoblotting, and (B) quantitative analysis of AnkB protein levels in hearts of both Ank2 fl/fl and Ank2 -cKO mice. (C-D) Immunoblots and quantitative analysis of total β-catenin and GAPDH in Ank2 -cKO-TD- vs vehicle-treated mice. (E-F) Immunoblots and quantitative analysis of phosphorylated β-catenin and GAPDH in Ank2 -cKO TD- vs vehicle-treated mice. Data presented using mean ± SEM and compared using analysis of variance with Tukey post hoc test or Student's t -test, n = 3-4, ∗∗ P < 0.01. Abbreviations as in and .

Journal: JACC: Basic to Translational Science

Article Title: Evaluation of Tideglusib as a Disease Modifying Therapy in Murine Models of Arrhythmogenic Cardiomyopathy

doi: 10.1016/j.jacbts.2025.03.013

Figure Lengend Snippet: Expression of AnkB, Total β-Catenin and Phosphorylated β-Catenin After Tideglusib Administration in Ank2 -cKO Mice (A) Validation of the Ank2 -cKO murine model via immunoblotting, and (B) quantitative analysis of AnkB protein levels in hearts of both Ank2 fl/fl and Ank2 -cKO mice. (C-D) Immunoblots and quantitative analysis of total β-catenin and GAPDH in Ank2 -cKO-TD- vs vehicle-treated mice. (E-F) Immunoblots and quantitative analysis of phosphorylated β-catenin and GAPDH in Ank2 -cKO TD- vs vehicle-treated mice. Data presented using mean ± SEM and compared using analysis of variance with Tukey post hoc test or Student's t -test, n = 3-4, ∗∗ P < 0.01. Abbreviations as in and .

Article Snippet: Membranes were incubated overnight at 4 °C in primary antibodies targeting AnkB (1:1,000, Covance, custom made), β-catenin (1:1,000, BD Biosciences, Cat. No. 610153), phospho-β-catenin (at Serine 33, Serine 37 and Threonine 41,1:1,000, Cell Signaling Technology, Cat. No. 9561), phospho-GSK-3β (at Serine 9, 1:1,000 Cell Signaling Technology, Cat. No. 9336S), Plakoglobin, JUP, (1:1,000, Abcam, Cat. No. Ab15153), Connexin-43, Cx-43, (1:1,000, Millipore-Sigma, Cat. No. C6219) and GAPDH (1:5,000, Fitzgerald Industries International, Cat. No. 10R-G109A).

Techniques: Expressing, Biomarker Discovery, Western Blot

Effects of Tideglusib on GSK-3β Phosphorylation and β-Catenin Phosphorylation in Dsg2 mut/mut Mice Immunoblots and quantitative analysis of (A) total GSK-3β, (B) phosphorylated form of GSK-3β, (C) total β-catenin and (D) phosphorylated form of β-catenin. Data presented using mean ± SEM and compared using Student's t -test (n = 8-9/group), ∗∗ P < 0.01.

Journal: JACC: Basic to Translational Science

Article Title: Evaluation of Tideglusib as a Disease Modifying Therapy in Murine Models of Arrhythmogenic Cardiomyopathy

doi: 10.1016/j.jacbts.2025.03.013

Figure Lengend Snippet: Effects of Tideglusib on GSK-3β Phosphorylation and β-Catenin Phosphorylation in Dsg2 mut/mut Mice Immunoblots and quantitative analysis of (A) total GSK-3β, (B) phosphorylated form of GSK-3β, (C) total β-catenin and (D) phosphorylated form of β-catenin. Data presented using mean ± SEM and compared using Student's t -test (n = 8-9/group), ∗∗ P < 0.01.

Article Snippet: Membranes were incubated overnight at 4 °C in primary antibodies targeting AnkB (1:1,000, Covance, custom made), β-catenin (1:1,000, BD Biosciences, Cat. No. 610153), phospho-β-catenin (at Serine 33, Serine 37 and Threonine 41,1:1,000, Cell Signaling Technology, Cat. No. 9561), phospho-GSK-3β (at Serine 9, 1:1,000 Cell Signaling Technology, Cat. No. 9336S), Plakoglobin, JUP, (1:1,000, Abcam, Cat. No. Ab15153), Connexin-43, Cx-43, (1:1,000, Millipore-Sigma, Cat. No. C6219) and GAPDH (1:5,000, Fitzgerald Industries International, Cat. No. 10R-G109A).

Techniques: Phospho-proteomics, Western Blot

Effect of ROBO1 or ROBO2 functional impairment in branching morphogenesis. a The upper panel is representative of untreated lung explants (0 ng/mL) at D0; the bottom panel represents lung explants treated with recombinant IgG protein (0 ng/mL) and several doses of recombinant ROBO1 or ROBO2 proteins at day 4 (D4). b Morphometric analysis of the number of peripheral airway buds of fetal rat lung explants treated with increasing concentrations of recombinant ROBO1 (black) and ROBO2 (gray) proteins. Results are expressed as the D4/D0 ratio. c Examples of representative blots are showed for each analysed protein. Protein expression levels of d ROBO; e SOX2; f SOX9; g total β-Catenin; h non-phospho (active) β-Catenin; and i BMP4 in normal explant cultures treated with recombinant rat ROBO1 Fc Chimera for ROBO1 inhibition (black line) or recombinant human ROBO2 Fc Chimera for ROBO2 functional impairment (gray line). Recombinant human IgG Fc was used as control (IgG). n ≥ 9 per protein/condition. Each lane represents a pooled-tissue sample, and relative expression was determined against β-Tubulin and IgG. The data are presented as means ± SEM. p < 0.05: α vs. IgG

Journal: Respiratory Research

Article Title: ROBO2 signaling in lung development regulates SOX2/SOX9 balance, branching morphogenesis and is dysregulated in nitrofen-induced congenital diaphragmatic hernia

doi: 10.1186/s12931-020-01568-w

Figure Lengend Snippet: Effect of ROBO1 or ROBO2 functional impairment in branching morphogenesis. a The upper panel is representative of untreated lung explants (0 ng/mL) at D0; the bottom panel represents lung explants treated with recombinant IgG protein (0 ng/mL) and several doses of recombinant ROBO1 or ROBO2 proteins at day 4 (D4). b Morphometric analysis of the number of peripheral airway buds of fetal rat lung explants treated with increasing concentrations of recombinant ROBO1 (black) and ROBO2 (gray) proteins. Results are expressed as the D4/D0 ratio. c Examples of representative blots are showed for each analysed protein. Protein expression levels of d ROBO; e SOX2; f SOX9; g total β-Catenin; h non-phospho (active) β-Catenin; and i BMP4 in normal explant cultures treated with recombinant rat ROBO1 Fc Chimera for ROBO1 inhibition (black line) or recombinant human ROBO2 Fc Chimera for ROBO2 functional impairment (gray line). Recombinant human IgG Fc was used as control (IgG). n ≥ 9 per protein/condition. Each lane represents a pooled-tissue sample, and relative expression was determined against β-Tubulin and IgG. The data are presented as means ± SEM. p < 0.05: α vs. IgG

Article Snippet: Blots were blocked in 5% bovine serum albumin and probed with primary antibodies to ROBO1 (1:500, ON, 4 oC; Cat No. sc25672, Santa Cruz Biotechnology Inc., USA), ROBO2 (1:250, ON, 4 oC; Cat No. sc16615, Santa Cruz Biotechnology Inc. USA), SOX2 (1:250, ON, 4 oC; Cat No. AF2018, R&D system, USA), SOX9 (1:250, ON, 4 oC; Cat No. AF3075, R&D system, USA), non-phospho (Active) β-Catenin (Ser33/37/Thr41) (1∶5000; Cat No. #4270, Cell Signaling Technology Inc., USA), total β-Catenin (1∶30,000; Cat No. #NBP1-54,467, NOVUS Biologicals, USA), and BMP4 (1:250, ON, 4 oC; Cat No. sc-6896, Santa Cruz Biotechnology Inc., USA) according to the manufacturer's instructions.

Techniques: Functional Assay, Recombinant, Expressing, Inhibition, Control

a Overview of the main changes in spatiotemporal distribution of ROBO1, ROBO2, SOX2 and SOX9 at pseudoglandular (E17.5) and saccular stages (E21.5) in hypoplastic (hyp) fetal lungs (lower panel). w/o without b A proposed model of ROBO regulation of ex vivo branching morphogenesis through BMP4, β-Catenin, SOX2 and SOX9

Journal: Respiratory Research

Article Title: ROBO2 signaling in lung development regulates SOX2/SOX9 balance, branching morphogenesis and is dysregulated in nitrofen-induced congenital diaphragmatic hernia

doi: 10.1186/s12931-020-01568-w

Figure Lengend Snippet: a Overview of the main changes in spatiotemporal distribution of ROBO1, ROBO2, SOX2 and SOX9 at pseudoglandular (E17.5) and saccular stages (E21.5) in hypoplastic (hyp) fetal lungs (lower panel). w/o without b A proposed model of ROBO regulation of ex vivo branching morphogenesis through BMP4, β-Catenin, SOX2 and SOX9

Article Snippet: Blots were blocked in 5% bovine serum albumin and probed with primary antibodies to ROBO1 (1:500, ON, 4 oC; Cat No. sc25672, Santa Cruz Biotechnology Inc., USA), ROBO2 (1:250, ON, 4 oC; Cat No. sc16615, Santa Cruz Biotechnology Inc. USA), SOX2 (1:250, ON, 4 oC; Cat No. AF2018, R&D system, USA), SOX9 (1:250, ON, 4 oC; Cat No. AF3075, R&D system, USA), non-phospho (Active) β-Catenin (Ser33/37/Thr41) (1∶5000; Cat No. #4270, Cell Signaling Technology Inc., USA), total β-Catenin (1∶30,000; Cat No. #NBP1-54,467, NOVUS Biologicals, USA), and BMP4 (1:250, ON, 4 oC; Cat No. sc-6896, Santa Cruz Biotechnology Inc., USA) according to the manufacturer's instructions.

Techniques: Ex Vivo

β-catenin is essential for CUG2-induced CSC-like phenotypes. (A) A549-VEC and A549-CUG2 cells were separated into cytosolic and nuclear fractions. β-catenin expression was determined by performing western blot analysis with an anti-β-catenin antibody. Phosphorylation states of β-catenin following treatment were detected using antibodies against Ser33/Ser37/Thr41, Ser45 and Ser675 of β-catenin. The cytosolic and nuclear fractions were confirmed by detecting actin and Sp1, respectively. (B) Total RNAs (3 µ g) were isolated from the A549-VECand A549-CUG2 cells, and cDNAs were synthesized using reverse transcriptase II. β-catenin gene sequences were amplified using specific primers by using an optimized PCR cycle and were visualized on 1.5% agarose gels following ethidium bromide staining. β-actin was used as an internal control. (C) A549-VEC and A549-CUG2 cells were transfected with the Top-Flash (1 µ g) or Fop-Flash (1 µ g) luciferase reporter vector and were harvested at 48 h after the transfection. Transfection efficiency was normalized with that of the β-galactosidase reporter vector pGK-βgal (1 µ g) during the measurement of luciferase activity. Results are an average of three experiments; bars indicate the means ± SD ( *** P<0.001, A549-VEC vs A549-CUG2 cells). (D) Transfection of efficiency of β-catenin siRNAs (#1 or #2) was confirmed by western blot analysis. (E) Migration of A549-CUG2 cells was measured with the wound healing assay at 24 h after control or β-catenin siRNAs (#1 and #2) transfection. Wound closure areas were monitored using a phase-contrast microscope at ×100 magnification, and the assay was repeated twice. (F) Invasion of A549-CUG2 cells transfected with control or β-catenin siRNAs (#1 and #2) was determined using the 48-well Boyden chamber. The chamber was assembled using Matrigel-coated polycarbonate filters. Scale bar indicates 100 µ m, and the assay was repeated twice. Each assay was performed in triplicate, and error bars indicate the means ± SD ( *** P<0.001, control vs. β-catenin siRNA). (G) A549-CUG2 cells (1,000 cells per well) transfected with control or β-catenin siRNAs (#1 and #2) were seeded in ultra-low attachment plates for 2, 4, or 6 days. The assay was performed in triplicate, and error bars indicate the means ± SD ( ** P<0.01 and *** P<0.001, control vs. β-catenin siRNA). Scale bars indicate 50 µ m. CUG2, cancer-upregulated gene 2.

Journal: International Journal of Oncology

Article Title: CGK062, a small chemical molecule, inhibits cancer upregulated gene 2-induced oncogenesis through NEK2 and β-catenin

doi: 10.3892/ijo.2019.4724

Figure Lengend Snippet: β-catenin is essential for CUG2-induced CSC-like phenotypes. (A) A549-VEC and A549-CUG2 cells were separated into cytosolic and nuclear fractions. β-catenin expression was determined by performing western blot analysis with an anti-β-catenin antibody. Phosphorylation states of β-catenin following treatment were detected using antibodies against Ser33/Ser37/Thr41, Ser45 and Ser675 of β-catenin. The cytosolic and nuclear fractions were confirmed by detecting actin and Sp1, respectively. (B) Total RNAs (3 µ g) were isolated from the A549-VECand A549-CUG2 cells, and cDNAs were synthesized using reverse transcriptase II. β-catenin gene sequences were amplified using specific primers by using an optimized PCR cycle and were visualized on 1.5% agarose gels following ethidium bromide staining. β-actin was used as an internal control. (C) A549-VEC and A549-CUG2 cells were transfected with the Top-Flash (1 µ g) or Fop-Flash (1 µ g) luciferase reporter vector and were harvested at 48 h after the transfection. Transfection efficiency was normalized with that of the β-galactosidase reporter vector pGK-βgal (1 µ g) during the measurement of luciferase activity. Results are an average of three experiments; bars indicate the means ± SD ( *** P<0.001, A549-VEC vs A549-CUG2 cells). (D) Transfection of efficiency of β-catenin siRNAs (#1 or #2) was confirmed by western blot analysis. (E) Migration of A549-CUG2 cells was measured with the wound healing assay at 24 h after control or β-catenin siRNAs (#1 and #2) transfection. Wound closure areas were monitored using a phase-contrast microscope at ×100 magnification, and the assay was repeated twice. (F) Invasion of A549-CUG2 cells transfected with control or β-catenin siRNAs (#1 and #2) was determined using the 48-well Boyden chamber. The chamber was assembled using Matrigel-coated polycarbonate filters. Scale bar indicates 100 µ m, and the assay was repeated twice. Each assay was performed in triplicate, and error bars indicate the means ± SD ( *** P<0.001, control vs. β-catenin siRNA). (G) A549-CUG2 cells (1,000 cells per well) transfected with control or β-catenin siRNAs (#1 and #2) were seeded in ultra-low attachment plates for 2, 4, or 6 days. The assay was performed in triplicate, and error bars indicate the means ± SD ( ** P<0.01 and *** P<0.001, control vs. β-catenin siRNA). Scale bars indicate 50 µ m. CUG2, cancer-upregulated gene 2.

Article Snippet: Antibodies against Smad2/3 (#5678), phosphorylated Smad2 (#3108), β-catenin (#9562), and phosphorylated β-catenin (Ser33/Ser37/Thr41, Ser45, or Ser675; #9561, #9564, or #4176, respectively) were purchased from Cell Signaling Biotechnology (Danvers, MA, USA).

Techniques: Expressing, Western Blot, Phospho-proteomics, Isolation, Synthesized, Reverse Transcription, Amplification, Staining, Control, Transfection, Luciferase, Plasmid Preparation, Activity Assay, Migration, Wound Healing Assay, Microscopy

CUG2-induced β-catenin phosphorylation is unique and differs from that induced by Wnt3a. (A) A549-VEC and A549-CUG2 cells were treated with wortmannin (10 µ M), H89 (10 µ M), PP2 (2.5 µ M) and DMSO (mock) in the presence of Wnt3a (100 ng/ml) or PBS as a vehicle for 12 h, and cell lysates were prepared. Proteins present in the cell lysates were separated by performing SDS-PAGE on 10% gels, and β-catenin and α-actin were detected using corresponding antibodies. (B and C) Proteins present in the lysates of A549-VEC cells treated with Wnt3a (100 ng/ml) or PBS, and of A549-CUG2 cells were separated by performing SDS-PAGE on 10% gels. Phosphorylation states of β-catenin following treatment were determined using antibodies against phosphorylated Ser33/Ser37/Thr41, Ser45 and Ser675 of β-catenin. (D) Lysates of A549-VEC and A549-CUG2 cells treated with a control or GSK3β siRNAs (#1 and #2) were separated by performing SDS-PAGE on 10% gels. GSK3β and phosphorylated GSK3β were detected by performing western blot with corresponding antibodies. CUG2, cancer-upregulated gene 2; GSK3β, glycogen synthase kinase 3β.

Journal: International Journal of Oncology

Article Title: CGK062, a small chemical molecule, inhibits cancer upregulated gene 2-induced oncogenesis through NEK2 and β-catenin

doi: 10.3892/ijo.2019.4724

Figure Lengend Snippet: CUG2-induced β-catenin phosphorylation is unique and differs from that induced by Wnt3a. (A) A549-VEC and A549-CUG2 cells were treated with wortmannin (10 µ M), H89 (10 µ M), PP2 (2.5 µ M) and DMSO (mock) in the presence of Wnt3a (100 ng/ml) or PBS as a vehicle for 12 h, and cell lysates were prepared. Proteins present in the cell lysates were separated by performing SDS-PAGE on 10% gels, and β-catenin and α-actin were detected using corresponding antibodies. (B and C) Proteins present in the lysates of A549-VEC cells treated with Wnt3a (100 ng/ml) or PBS, and of A549-CUG2 cells were separated by performing SDS-PAGE on 10% gels. Phosphorylation states of β-catenin following treatment were determined using antibodies against phosphorylated Ser33/Ser37/Thr41, Ser45 and Ser675 of β-catenin. (D) Lysates of A549-VEC and A549-CUG2 cells treated with a control or GSK3β siRNAs (#1 and #2) were separated by performing SDS-PAGE on 10% gels. GSK3β and phosphorylated GSK3β were detected by performing western blot with corresponding antibodies. CUG2, cancer-upregulated gene 2; GSK3β, glycogen synthase kinase 3β.

Article Snippet: Antibodies against Smad2/3 (#5678), phosphorylated Smad2 (#3108), β-catenin (#9562), and phosphorylated β-catenin (Ser33/Ser37/Thr41, Ser45, or Ser675; #9561, #9564, or #4176, respectively) were purchased from Cell Signaling Biotechnology (Danvers, MA, USA).

Techniques: Phospho-proteomics, SDS Page, Control, Western Blot

CUG2-activated NEK2 is responsible for the phosphorylation of β-catenin at Ser33/Ser37. (A) Lysates of A549-VEC and A549-CUG2 cells were separated by performing SDS-PAGE on 10% gels, and NEK2 was detected by performing western blot analysis with anti-NEK2 antibody. (B) Levels of NEK2 and β-catenin phosphorylated at Ser33/Ser37 (p-β-catenin; p-Ser33/Ser37) in A549-VEC and A549-CUG2 cells were determined by performing immunofluorescence microscopy with Alexa Fluor 594-conjugated goat anti-mouse IgG (red) and Alexa Fluor 488-conjugated goat anti-rabbit IgG (green), respectively. For performing nuclear staining, DAPI was added before mounting in glycerol. Scale bar indicates 10 µ m. (C) β-catenin was pulled down from the lysates of A549-VEC and A549-CUG2 cells by using an anti-β-catenin antibody. NEK2 present in the immunoprecipitates was detected using an anti-NEK2 antibody, and β-catenin present in the immunoprecipitates was detected as a loading control by using an anti-β-catenin antibody. (D) NEK2 was pulled down from A549-VEC and A549-CUG2 cells by using an anti-NEK2 antibody or isotype IgG as a control. The reaction mixture for the NEK2 kinase assay, including immunoprecipitates as NEK2 kinase, recombinant GST-β-catenin as a substrate, ATP, and a reaction buffer, was incubated at 30°C for 1 h. NEK2 kinase activity was analyzed by determining the phosphorylation of GST-β-catenin at Ser33/Ser37 by performing immunoblotting, and β-catenin levels were examined as a loading control. (E) Lysates of A549-CUG2 cells transfected with the control or NEK2 siRNAs (#1 and #2) were separated by performing SDS-PAGE on 10% gels. Phosphorylation states of β-catenin following treatment were detected using antibodies against Ser33/Ser37/Thr41, Ser45 and Ser675 of β-catenin. (F) Following transfection with control or NEK2 siRNA#1, the levels of p-β-catenin (p-Ser33/Ser37) in A549-CUG2 cells were detected by performing immunofluorescence microscopy with Alexa Fluor 488-conjugated goat anti-rabbit IgG (green). For performing nuclear staining, DAPI was added before mounting in glycerol. Scale bar indicates 10 µ m. CUG2, cancer-upregulated gene 2; NEK2, never in mitosis gene A-related kinase 2.

Journal: International Journal of Oncology

Article Title: CGK062, a small chemical molecule, inhibits cancer upregulated gene 2-induced oncogenesis through NEK2 and β-catenin

doi: 10.3892/ijo.2019.4724

Figure Lengend Snippet: CUG2-activated NEK2 is responsible for the phosphorylation of β-catenin at Ser33/Ser37. (A) Lysates of A549-VEC and A549-CUG2 cells were separated by performing SDS-PAGE on 10% gels, and NEK2 was detected by performing western blot analysis with anti-NEK2 antibody. (B) Levels of NEK2 and β-catenin phosphorylated at Ser33/Ser37 (p-β-catenin; p-Ser33/Ser37) in A549-VEC and A549-CUG2 cells were determined by performing immunofluorescence microscopy with Alexa Fluor 594-conjugated goat anti-mouse IgG (red) and Alexa Fluor 488-conjugated goat anti-rabbit IgG (green), respectively. For performing nuclear staining, DAPI was added before mounting in glycerol. Scale bar indicates 10 µ m. (C) β-catenin was pulled down from the lysates of A549-VEC and A549-CUG2 cells by using an anti-β-catenin antibody. NEK2 present in the immunoprecipitates was detected using an anti-NEK2 antibody, and β-catenin present in the immunoprecipitates was detected as a loading control by using an anti-β-catenin antibody. (D) NEK2 was pulled down from A549-VEC and A549-CUG2 cells by using an anti-NEK2 antibody or isotype IgG as a control. The reaction mixture for the NEK2 kinase assay, including immunoprecipitates as NEK2 kinase, recombinant GST-β-catenin as a substrate, ATP, and a reaction buffer, was incubated at 30°C for 1 h. NEK2 kinase activity was analyzed by determining the phosphorylation of GST-β-catenin at Ser33/Ser37 by performing immunoblotting, and β-catenin levels were examined as a loading control. (E) Lysates of A549-CUG2 cells transfected with the control or NEK2 siRNAs (#1 and #2) were separated by performing SDS-PAGE on 10% gels. Phosphorylation states of β-catenin following treatment were detected using antibodies against Ser33/Ser37/Thr41, Ser45 and Ser675 of β-catenin. (F) Following transfection with control or NEK2 siRNA#1, the levels of p-β-catenin (p-Ser33/Ser37) in A549-CUG2 cells were detected by performing immunofluorescence microscopy with Alexa Fluor 488-conjugated goat anti-rabbit IgG (green). For performing nuclear staining, DAPI was added before mounting in glycerol. Scale bar indicates 10 µ m. CUG2, cancer-upregulated gene 2; NEK2, never in mitosis gene A-related kinase 2.

Article Snippet: Antibodies against Smad2/3 (#5678), phosphorylated Smad2 (#3108), β-catenin (#9562), and phosphorylated β-catenin (Ser33/Ser37/Thr41, Ser45, or Ser675; #9561, #9564, or #4176, respectively) were purchased from Cell Signaling Biotechnology (Danvers, MA, USA).

Techniques: Phospho-proteomics, SDS Page, Western Blot, Immunofluorescence, Microscopy, Staining, Control, Kinase Assay, Recombinant, Incubation, Activity Assay, Transfection

CGK062 treatment destabilizes β-catenin in a proteasome- and PKCα- dependent manner. (A) A549-CUG2 cells were treated with CGK062 (0, 1, 10, 50 and 100 µ M) for 24 h, and β-catenin levels were measured by performing western blot analysis with an anti-β-catenin antibody. (B) A549-CUG2 cells were transfected with the Top-Flash (1 µ g) or Fop-Flash (1 µ g) luciferase reporter vector in the presence of CGK062 (50 µ M) and were harvested at 48 h following transfection. Transfection efficiency was normalized with that of the β-galactosidase reporter vector pGK-βgal (1 µ g) during the measurement of luciferase activity. Results shown are an average of 3 experiments; bars indicate the means ± SD ( *** P<0.001, 0 vs. 10 µ M, 0 vs. 50 µ M). (C) Total RNAs (3 µ g) were isolated from A549-CUG2 cells treated with or without CGK062 (50 µ M), and cDNAs were synthesized using reverse transcriptase II. β-catenin gene sequences were amplified using specific primers by using an optimized PCR cycle and were visualized on 1.5% agarose gels following ethidium bromide staining. β-actin was used as an internal control. (D) A549-CUG2 cells were treated with MG132 (1 µ M) for 8 h in the absence or presence of CGK062 (50 µ M) and were harvested. β-catenin levels were measured by performing western blot analysis with an anti-β-catenin antibody. (E) A549-CUG2 cells were treated with BMI (7.5 µ M), a specific PKCα inhibitor, or were transfected with a control and PKCα siRNAs (#1 or #2) in the absence or presence of CGK062 (50 µ M) for 24 h. Transfection efficiency of PKCα siRNAs (#1 or #2) was confirmed by western blot analysis. β-catenin levels were measured by performing western blot analysis with an anti-β-catenin antibody. CUG2, cancer-upregulated gene 2; PKC, protein kinase C.

Journal: International Journal of Oncology

Article Title: CGK062, a small chemical molecule, inhibits cancer upregulated gene 2-induced oncogenesis through NEK2 and β-catenin

doi: 10.3892/ijo.2019.4724

Figure Lengend Snippet: CGK062 treatment destabilizes β-catenin in a proteasome- and PKCα- dependent manner. (A) A549-CUG2 cells were treated with CGK062 (0, 1, 10, 50 and 100 µ M) for 24 h, and β-catenin levels were measured by performing western blot analysis with an anti-β-catenin antibody. (B) A549-CUG2 cells were transfected with the Top-Flash (1 µ g) or Fop-Flash (1 µ g) luciferase reporter vector in the presence of CGK062 (50 µ M) and were harvested at 48 h following transfection. Transfection efficiency was normalized with that of the β-galactosidase reporter vector pGK-βgal (1 µ g) during the measurement of luciferase activity. Results shown are an average of 3 experiments; bars indicate the means ± SD ( *** P<0.001, 0 vs. 10 µ M, 0 vs. 50 µ M). (C) Total RNAs (3 µ g) were isolated from A549-CUG2 cells treated with or without CGK062 (50 µ M), and cDNAs were synthesized using reverse transcriptase II. β-catenin gene sequences were amplified using specific primers by using an optimized PCR cycle and were visualized on 1.5% agarose gels following ethidium bromide staining. β-actin was used as an internal control. (D) A549-CUG2 cells were treated with MG132 (1 µ M) for 8 h in the absence or presence of CGK062 (50 µ M) and were harvested. β-catenin levels were measured by performing western blot analysis with an anti-β-catenin antibody. (E) A549-CUG2 cells were treated with BMI (7.5 µ M), a specific PKCα inhibitor, or were transfected with a control and PKCα siRNAs (#1 or #2) in the absence or presence of CGK062 (50 µ M) for 24 h. Transfection efficiency of PKCα siRNAs (#1 or #2) was confirmed by western blot analysis. β-catenin levels were measured by performing western blot analysis with an anti-β-catenin antibody. CUG2, cancer-upregulated gene 2; PKC, protein kinase C.

Article Snippet: Antibodies against Smad2/3 (#5678), phosphorylated Smad2 (#3108), β-catenin (#9562), and phosphorylated β-catenin (Ser33/Ser37/Thr41, Ser45, or Ser675; #9561, #9564, or #4176, respectively) were purchased from Cell Signaling Biotechnology (Danvers, MA, USA).

Techniques: Western Blot, Transfection, Luciferase, Plasmid Preparation, Activity Assay, Isolation, Synthesized, Reverse Transcription, Amplification, Staining, Control

CGK062 treatment decreases NEK2 expression and kinase activity in A549-CUG2 cells. (A) Lysates of A549-CUG2 cells treated with CGK062 (0, 10, 30, 40 and 50 µ M) for 24 h were separated by performing SDS-PAGE on 10% gels. The expression of NEK2, β-catenin, E-cadherin, N-cadherin and vimentin was detected by performing western blot analysis with corresponding antibodies. (B) Levels of NEK2 and p-β-catenin (p-Ser33/Ser37) in A549-CUG2 cells treated with CGK062 (50 µ M) or DMSO as Mock were detected by performing immunofluorescence microscopy with Alexa Fluor 594-conjugated goat anti-mouse IgG (red) and Alexa Fluor 488-conjugated goat anti-rabbit IgG (green), respectively. For performing nuclear staining, DAPI was added before mounting in glycerol. Scale bar indicates 10 µ m. (C) NEK2 was pulled down from A549-VEC and A549-CUG2 cells treated with CGK062 (50 µ M) or DMSO by using the anti-NEK2 antibody or isotype IgG as a control. The reaction mixture for the NEK2 kinase assay was incubated at 30°C for 1 h. NEK2 kinase activity was analyzed by detecting the phosphorylation of GST-β-catenin at Ser33/Ser37 by performing western blot analysis, and β-catenin levels were examined as a loading control. CUG2, cancer-upregulated gene 2; NEK2, never in mitosis gene A-related kinase 2.

Journal: International Journal of Oncology

Article Title: CGK062, a small chemical molecule, inhibits cancer upregulated gene 2-induced oncogenesis through NEK2 and β-catenin

doi: 10.3892/ijo.2019.4724

Figure Lengend Snippet: CGK062 treatment decreases NEK2 expression and kinase activity in A549-CUG2 cells. (A) Lysates of A549-CUG2 cells treated with CGK062 (0, 10, 30, 40 and 50 µ M) for 24 h were separated by performing SDS-PAGE on 10% gels. The expression of NEK2, β-catenin, E-cadherin, N-cadherin and vimentin was detected by performing western blot analysis with corresponding antibodies. (B) Levels of NEK2 and p-β-catenin (p-Ser33/Ser37) in A549-CUG2 cells treated with CGK062 (50 µ M) or DMSO as Mock were detected by performing immunofluorescence microscopy with Alexa Fluor 594-conjugated goat anti-mouse IgG (red) and Alexa Fluor 488-conjugated goat anti-rabbit IgG (green), respectively. For performing nuclear staining, DAPI was added before mounting in glycerol. Scale bar indicates 10 µ m. (C) NEK2 was pulled down from A549-VEC and A549-CUG2 cells treated with CGK062 (50 µ M) or DMSO by using the anti-NEK2 antibody or isotype IgG as a control. The reaction mixture for the NEK2 kinase assay was incubated at 30°C for 1 h. NEK2 kinase activity was analyzed by detecting the phosphorylation of GST-β-catenin at Ser33/Ser37 by performing western blot analysis, and β-catenin levels were examined as a loading control. CUG2, cancer-upregulated gene 2; NEK2, never in mitosis gene A-related kinase 2.

Article Snippet: Antibodies against Smad2/3 (#5678), phosphorylated Smad2 (#3108), β-catenin (#9562), and phosphorylated β-catenin (Ser33/Ser37/Thr41, Ser45, or Ser675; #9561, #9564, or #4176, respectively) were purchased from Cell Signaling Biotechnology (Danvers, MA, USA).

Techniques: Expressing, Activity Assay, SDS Page, Western Blot, Immunofluorescence, Microscopy, Staining, Control, Kinase Assay, Incubation, Phospho-proteomics

Peptides identified by LC ESMS from HNE-modified cathepsin B

Journal:

Article Title: Hydroxynonenal inactivates cathepsin B by forming Michael adducts with active site residues

doi:

Figure Lengend Snippet: Peptides identified by LC ESMS from HNE-modified cathepsin B

Article Snippet: In addition, no other anti-HNE immunoreactive peptides were detected by antibody dot blot analysis of chromatography fractions in separate RP HPLC of tryptic digests of HNE-modified cathepsin B (not shown). table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Molecular mass Peptides Sequence position Retention time (min) Calculated Observed Error a (Da) Sequence Cathepsin B, A-chain tryptic peptides AT1 1–8 20.2 933.4 933.8 0.4 LPESFDAR AT2* b 9–18 21.7 1271.6 1271.9 0.3 EQWPNCPTIK AT3 19–21 5.6 416.2 416.4 0.2 EIR AT4** 22–41 28.0 2173.3av 2173.4 0.1 DQGSCGSCWAFGAVEAISDR AT4-HNE modified* 22–41 32.1, 32.7 2274.4av 2274.0 0.4 DQGSCGSCWAFGAVEAISDR AT5* 42–47 17.8 742.3 742.5 0.2 ICIHSN Cathepsin B, B-chain tryptic peptides BT1**** 1–36 30.4 3970.4av 3970.4 0 VNVEVSAEDMLTCCGGECGDGCNGGFPSGAWNFWTK BT2 37–37 .NS 146.1 NS — K BT3*** 38–78 .ND 4447.9av ND G GLVSGGLYNSHVGCRPYSIPPCEHHVNGSRPPCTGEGDTPK BT4* 79–81 5.4 393.2 393.4 0.2 CST BT5 82–92 17.7 1287.5 1287.9 0.4 FWTKKGLVSGG BT6 93–95 .ND 390.2 ND — EDK BT7* 96–109 18.3 1598.7 1598.8 0.1 HFGCSSYSVANNEK BT8 110–117 22.7 995.5 995.6 0.1 EIMAEIYK BT9 118–135 31.5 2006.3av 2006.3 0 NGPVEGAFSVYSDFLLYK BT10 136–153 22.9 1898.1av 1897.8 0.3 SGVYQHVSGEIMGGHAIR BT10-HNE modified 136–153 25.4, 30.3 2056.2 2056.8 0.4 SGVYQHVSGEIMGGHAIR BT11 154–183 33.8 3430.7av 3430.6 0.1 ILGWGVENGTPYWLVGNSWNTDWGDNGFFK BT12 184–186 14.4 400.3 400.4 0.2 ILR BT13** 187–204 .ND 1961.2av ND — GQDHCGIESEIVAGMPCT Open in a separate window Bovine cathepsin B peptides identified by LC ESMS in Fig. 4 are listed by subunit, tryptic peptide, residues, total ion current retention time, calculated and observed masses, and amino acid sequences.

Techniques: Modification

Fig. 5 AP3S1 exhibition in ovarian cancer single-cell sequencing results. A Single-cell sequencing results classifying cell subgroups in ovarian cancer tissues. B Cell subgroups identified as immune cell clusters. C Expression level of AP3S1 in immune cell clusters. D Proportions of various immune cells. E Proportions of different immune cells in various ovarian cancer samples. F Expression of AP3S1 in different immune cells. G Expression of DNA repair pathways in cell subgroups. H Expression of oxidative phosphorylation pathways in cell subgroups. I Expression of TGF-β pathways in cell subgroups

Journal: European journal of medical research

Article Title: Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.

doi: 10.1186/s40001-024-01814-7

Figure Lengend Snippet: Fig. 5 AP3S1 exhibition in ovarian cancer single-cell sequencing results. A Single-cell sequencing results classifying cell subgroups in ovarian cancer tissues. B Cell subgroups identified as immune cell clusters. C Expression level of AP3S1 in immune cell clusters. D Proportions of various immune cells. E Proportions of different immune cells in various ovarian cancer samples. F Expression of AP3S1 in different immune cells. G Expression of DNA repair pathways in cell subgroups. H Expression of oxidative phosphorylation pathways in cell subgroups. I Expression of TGF-β pathways in cell subgroups

Article Snippet: Ovarian cancer cells were subjected to protein extraction for Western blotting analysis after transfection with 80 nM AP3S1-siRNA for 48 h. An activator of the TGF-β signaling pathway known as, SRI-011381 (HY-100347, MCE), was applied at a concentration of 10 μM, and continued treatment was continued for 12 h post-transfection.

Techniques: Single Cell, Sequencing, Expressing, Phospho-proteomics

Fig. 10 AP3S1 regulates EMT in ovarian cancer through the TGF-β pathway. A Significant inhibition of TGF-β and EMT pathways in ovarian cancer cells after AP3S1 knockdown. B The TGF-β pathway activator SRI-011381 rescues the decreased expression of TGF-β pathway and EMT-related proteins caused by AP3S1 knockdown. C Pirfenidone further exacerbates the decreased expression of TGF-β pathway and EMT-related proteins caused by AP3S1 knockdown. All data are mean ± SD. Significance calculated using the unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Representative data are from three independent experiments

Journal: European journal of medical research

Article Title: Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.

doi: 10.1186/s40001-024-01814-7

Figure Lengend Snippet: Fig. 10 AP3S1 regulates EMT in ovarian cancer through the TGF-β pathway. A Significant inhibition of TGF-β and EMT pathways in ovarian cancer cells after AP3S1 knockdown. B The TGF-β pathway activator SRI-011381 rescues the decreased expression of TGF-β pathway and EMT-related proteins caused by AP3S1 knockdown. C Pirfenidone further exacerbates the decreased expression of TGF-β pathway and EMT-related proteins caused by AP3S1 knockdown. All data are mean ± SD. Significance calculated using the unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Representative data are from three independent experiments

Article Snippet: Ovarian cancer cells were subjected to protein extraction for Western blotting analysis after transfection with 80 nM AP3S1-siRNA for 48 h. An activator of the TGF-β signaling pathway known as, SRI-011381 (HY-100347, MCE), was applied at a concentration of 10 μM, and continued treatment was continued for 12 h post-transfection.

Techniques: Inhibition, Knockdown, Expressing

(A) Expression of indicated mRNAs in Mefs was monitored by RT-qPCR after treatment of the cells with LiCl (10 mM) for 24 h. Results are expressed in arbitrary units (a.u.). (B) Expression of Dlk-1 mRNA in WT and KO Mefs was monitored by RT-qPCR at D0 and D7 of differentiation. Normalisation and expression was done as in <xref ref-type=Fig. 1D . (C) Western Blot detection of WT and KO Mef whole cell extracts treated as in (A) using an anti-Dlk-1 antibody is shown. (D) Prmt5 recruitment to A and B regions of the Dlk-1 promoter in WT and KO Mefs was analysed by ChIP at D0 and D7. Values are expressed as the percentage of immunoprecipitated (ip) chromatin relative to input and are the mean±s.e.m. of triplicates. No antibody (noAb) was used as negative control. (E) Immunoprecipitation was performed as in (D) to assess the recruitment of activated β-catenin (β-cat) to three regions of the Dlk-1 promoter: two of them encompass the TCF binding sites 1 and 2 (TCFbs1 and TCFbs2), the third one is B, as in (D). (F) Expression of Dlk-1 mRNA in sh Copr5 F442A-treated cells was monitored by RT-qPCR upon inactivation of Dlk-1 using sh RNA (sh Dlk-1 ) encoding retroviral particles. A scramble sh RNA (sh Scr ) was used as control. Normalisation and expression were performed as in (B). (G) O Red Oil staining at D6 of sh Copr5 F442A-treated cells infected as in (F). *: non specific band. " width="100%" height="100%">

Journal: Biology Open

Article Title: The Wnt-target gene Dlk-1 is regulated by the Prmt5-associated factor Copr5 during adipogenic conversion

doi: 10.1242/bio.201411247

Figure Lengend Snippet: (A) Expression of indicated mRNAs in Mefs was monitored by RT-qPCR after treatment of the cells with LiCl (10 mM) for 24 h. Results are expressed in arbitrary units (a.u.). (B) Expression of Dlk-1 mRNA in WT and KO Mefs was monitored by RT-qPCR at D0 and D7 of differentiation. Normalisation and expression was done as in Fig. 1D . (C) Western Blot detection of WT and KO Mef whole cell extracts treated as in (A) using an anti-Dlk-1 antibody is shown. (D) Prmt5 recruitment to A and B regions of the Dlk-1 promoter in WT and KO Mefs was analysed by ChIP at D0 and D7. Values are expressed as the percentage of immunoprecipitated (ip) chromatin relative to input and are the mean±s.e.m. of triplicates. No antibody (noAb) was used as negative control. (E) Immunoprecipitation was performed as in (D) to assess the recruitment of activated β-catenin (β-cat) to three regions of the Dlk-1 promoter: two of them encompass the TCF binding sites 1 and 2 (TCFbs1 and TCFbs2), the third one is B, as in (D). (F) Expression of Dlk-1 mRNA in sh Copr5 F442A-treated cells was monitored by RT-qPCR upon inactivation of Dlk-1 using sh RNA (sh Dlk-1 ) encoding retroviral particles. A scramble sh RNA (sh Scr ) was used as control. Normalisation and expression were performed as in (B). (G) O Red Oil staining at D6 of sh Copr5 F442A-treated cells infected as in (F). *: non specific band.

Article Snippet: Anti-Prmt5 and -β-catenin (S33/37/41) antibodies (Euromedex and Cell Signaling, respectively) were used for ChIP, as described ( ).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Immunoprecipitation, Negative Control, Binding Assay, Retroviral, Control, Staining, Infection